SELUTION SLR™ 014 In-stent Restenosis

Status Recruiting

Clinical Trial Summary

Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or DES and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR™ 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized to SOC will be treated with BA. The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR™ 014 DEB in all patients.

Clinical Trial Description

Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial will enroll up to 418 randomized subjects (including up to 60 subjects in an angiographic and optical coherence tomography [OCT] sub-study) at up to 80 sites in the United States (US), Canada, Brazil, and Europe (EU). A minimum of 50% of the subjects will be enrolled in the US. Subjects with previous bare-metal stent (BMS) or DES and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR™ 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized to SOC will be treated with BA. The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR™ 014 DEB group. A subset of up to 60 subjects will be enrolled in the angiographic and OCT sub-study and undergo planned angiographic and OCT follow-up within 30 days after completion of the 12-month primary endpoint clinical follow-up/assessment. ;

Study Design

Related Conditions & MeSH terms

Coronary Restenosis

Clinical Trial Details

NCT number	NCT04280029
Study type	Interventional
Source	M.A. Med Alliance S.A.
Contact	Michelle Alamo
Phone	267-218-2816
Email	michelle.alamo@cordis.com
Status	Recruiting
Phase	N/A
Start date	July 6, 2020
Completion date	November 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01205776` - EXCEL Clinical Trial	N/A
Active, not recruiting	`NCT04475380` - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Completed	`NCT02263313` - EGO-COMBO Clinical End-point Extension Study Beyond 36 Months	N/A
Completed	`NCT00248066` - Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries	Phase 2
Completed	`NCT00148356` - Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries	Phase 2/Phase 3
Active, not recruiting	`NCT02508714` - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents	N/A
Completed	`NCT01274234` - OCT Evaluation of Healing of COMBO Stent	Phase 1/Phase 2
Completed	`NCT01205789` - EXCEL Clinical Trial (Universal Registry)	N/A
Recruiting	`NCT00426049` - Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation	Phase 3
Terminated	`NCT00243308` - Serp-1 for the Treatment of Acute Coronary Syndrome	Phase 2
Completed	`NCT00180466` - PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions	N/A
Completed	`NCT00859183` - Oral Sirolimus for In-Stent Restenosis	Phase 4
Completed	`NCT03667313` - Treatment of In-Stent Restenosis 2 Study	Phase 3
Recruiting	`NCT05089864` - STAR and Deferred Stenting Study	N/A
Active, not recruiting	`NCT02175706` - DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity	N/A
Completed	`NCT01249027` - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Completed	`NCT01331707` - DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population	Phase 4
Recruiting	`NCT00500279` - Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial	Phase 4
Completed	`NCT00402272` - SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe	Phase 4
Completed	`NCT01171820` - SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

SELUTION SLR™ 014 In-stent Restenosis — SELUTION4ISR

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms